The chronically inflamed central nervous system provides niches for long-lived plasma cells by Pollok, K. et al.
RESEARCH Open Access
The chronically inflamed central nervous
system provides niches for long-lived
plasma cells
Karolin Pollok1,4,5, Ronja Mothes1,4,5, Carolin Ulbricht1,4,5, Alina Liebheit1, Jan David Gerken1, Sylvia Uhlmann1,
Friedemann Paul3,6, Raluca Niesner2, Helena Radbruch4*† and Anja Erika Hauser1,5*†
Abstract
Although oligoclonal bands in the cerebrospinal fluid have been a hallmark of multiple sclerosis diagnosis for over
three decades, the role of antibody-secreting cells in multiple sclerosis remains unclear. T and B cells are critical for
multiple sclerosis pathogenesis, but increasing evidence suggests that plasma cells also contribute, through secretion
of autoantibodies. Long-lived plasma cells are known to drive various chronic inflammatory conditions as e.g. systemic
lupus erythematosus, however, to what extent they are present in autoimmune central nervous system inflammation
has not yet been investigated. In brain biopsies from multiple sclerosis patients and other neurological diseases, we
could detect non-proliferating plasma cells (CD138+Ki67−) in the parenchyma. Based on this finding, we hypothesized
that long-lived plasma cells can persist in the central nervous system (CNS). In order to test this hypothesis, we adapted
the multiple sclerosis mouse model experimental autoimmune encephalomyelitis to generate a B cell memory
response. Plasma cells were found in the meninges and the parenchyma of the inflamed spinal cord, surrounded by
tissue areas resembling survival niches for these cells, characterized by an up-regulation of chemokines (CXCL12),
adhesion molecules (VCAM-1) and survival factors (APRIL and BAFF). In order to determine the lifetime of plasma cells
in the chronically inflamed CNS, we labeled the DNA of proliferating cells with 5-ethynyl-2′-deoxyuridine (EdU). Up to
five weeks later, we could detect EdU+ long-lived plasma cells in the murine CNS. To our knowledge, this is the first
study describing non-proliferating plasma cells directly in the target tissue of a chronic inflammation in humans, as well
as the first evidence demonstrating the ability of plasma cells to persist in the CNS, and the ability of the chronically
inflamed CNS tissue to promote this persistence. Hence, our results suggest that the CNS provides survival niches for
long-lived plasma cells, similar to the niches found in other organs. Targeting these cells in the CNS offers new
perspectives for treatment of chronic autoimmune neuroinflammatory diseases, especially in patients who do not
respond to conventional therapies.
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Introduction
Multiple sclerosis is a chronic autoimmune disease charac-
terized by demyelination and neurodegeneration of the
central nervous system (CNS), leading to long-lasting
disability. The pathology of multiple sclerosis is not fully
understood. Among the hallmarks in the diagnosis of
multiple sclerosis is the presence of oligoclonal bands in
the cerebrospinal fluid, indicative of certain clones of
antibody-producing cells in the CNS compartment [48, 69].
However, the contribution of intracerebral plasma cells to
the pathogenesis of multiple sclerosis has not been eluci-
dated, and the relationship between those plasma cells and
other plasma cell compartments in the body is not clear. A
recent publication reported a correlation between disease
activity and the number of autoreactive plasma cells present
in the bone marrow, but not in the spleen, using a B cell-
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dependent experimental autoimmune encephalomyelitis
(EAE) model [8].
In other neuroinflammatory diseases, specific targets for
autoreactive antibodies have been identified in the CNS,
e.g. anti-aquaporin-4 (AQP-4) and anti-N-methyl-D-aspar-
tate receptor (NMDAR) [29, 31]. Plasma cells are found in
the chronically inflamed CNS [16, 50, 56], and although oli-
goclonal bands are known to persist over time in patients
[71, 74], few information is available on the life-span of
these antibody-producing cells. From other chronic
autoimmune conditions like lupus, it is known that
long-lived plasma cells contribute to progression of
the disease [26]. Plasma cell survival depends on
extrinsic factors such as cytokines, for example A
proliferation inducing ligand (APRIL) and IL-6, as
well as the chemokine CXCL12 [58], with the conse-
quence that long-lived plasma cell survival can only
occur in specialized multicellular niches that produce
all three factors. In humans, there are several diseases
in which the production of pathogenic autoantibodies
correlates with disease activity such as in systemic
lupus erythematosus [23]. Therapeutic plasma ex-
change in multiple sclerosis patients with high dis-
ease activity provides improvement of disability
status [15, 72], and, recently, antibodies targeting
axoglial neurofascin have been shown to be capable
of worsening disease upon transfer into animal
models of EAE [36, 43] and may also play a role in
human disease [12]. In marmosets local meningeal T and
plasma cell infiltration correlates with subcortical
demyelination [30]. In addition, complete depletion of
auto-antibodies ameliorates EAE severity in mice immu-
nized with recombinant human myelin oligodendrocyte
glycoprotein (rhMOG) peptide [7].
An important role for T and B cells in the pathogen-
esis of multiple sclerosis is indisputable [24]. A clonal
expansion of B cells in the CNS has been proposed to
occur in clusters of B cells which resemble follicular
structures [25], however, the role of different lymphocyte
subsets within the CNS during chronic neuroinflamma-
tion is not well investigated. As anti-CD20 treatment has
proven to be successful in the treatment of multiple
sclerosis [21, 22], B cells have become a focus of re-
search in neuroinflammation [2, 64]. However, various B
cell subsets have been shown to act either pro- or anti-
inflammatory in multiple sclerosis and EAE, and the
proposed involvement of B cells in neuroinflammatory
processes includes multiple functions such as antigen
presentation, cytokine production and production of auto-
reactive antibodies [2, 32]. More importantly, plasma cells
are not targeted by anti-CD20 therapy [23], and studies
with Atacicept, which targets plasma cells, were stopped
[19], raising the question which role residual plasma cells
play in disease progression.
To investigate the persistence of plasma cells during neu-
roinflammation, we induced EAE in C57BL/6 mice via in-
jection of rhMOG, a regimen shown to induce a B cell-
and antibody-dependent disease [39, 42, 49]. To overcome
the monophasic EAE course in C57BL/6 mice and more
closely mimic a memory immune response where long-
lived plasma cells are generated [20], we boosted the mice
with rhMOG, thereby inducing a second active EAE phase,
characterized by an increase in MOG-specific antibody ti-
ters in serum. Plasma cells were histologically investigated
during the course of EAE. Furthermore, to determine the
plasma cell lifetime, we performed 5-ethynyl-2′-deoxyuri-
dine (EdU) pulse-chase labeling experiments and were able
to identify long-lived plasma cells in the chronically in-
flamed murine spinal cord. The microenvironment of these
long-lived plasma cells resembled the molecular compos-
ition of their physiological bone marrow survival niches,
with an up-regulation of soluble factors known to attract to
and retain plasma cells in their niches, as well as survival
factors known to promote plasma cell longevity in the bone
marrow. Hence, the CNS -an organ virtually void of periph-
eral immune cells in healthy individuals- can become a site
of persistent immune memory, and may thereby contribute
to the chronification of neuroinflammation.
Material and methods
Study approval
The study of human material was carried out according
to the national ethics guidelines and legal regulations re-
garding the use of archival material.
All mouse experiments were performed according to
institutional guidelines and German Federal laws on ani-
mal protection under the licenses G0081/10 and G0076/
13 (LaGeSo Berlin).
Human samples
We investigated archival paraffin-embedded biopsy tissue
from patients who had been diagnosed in the Department
of Neuropathology, Charité - Universitätsmedizin Berlin
with inflammatory demyelination of the central nervous
system (CNS) consistent with multiple sclerosis, and with
confirmed plasma cell infiltration in their tissue, or with
other neurological diseases (OND) (Table 1). All patients
with multiple sclerosis fulfilled clinical diagnosis criteria
according to McDonald et al. [54]. None of the study
authors was involved in decision making with respect to
biopsy. Biopsies were taken of white matter lesions. Lesion
location of autopsy specimens is detailed in Table 2.
Autopsy samples were obtained from the Netherlands
Brain Bank (NBB), Netherlands Institute for Neuroscience,
Amsterdam. All material was collected from donors from
whom written informed consent for a brain autopsy and
the use of the material and clinical information for research
purposes had been obtained by the NBB.
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Mice
C57BL/6 J mice were purchased from Charles River and
maintained at the DRFZ. C57BL/6 J mice with Th back-
ground (expression of MOG-specific B cell receptor
[37]) were bred and housed under specific pathogen-free
conditions at the animal facility of the Federal Institute
for Risk Assessment (BfR, Berlin, Germany). For all in
vivo experiments, C57BL/6 J mice were used. Th mice
were used only as donors for serum to assemble a rela-
tive standard in the ELISA experiments, as a positive
control for MOG-specific antibodies.
Induction and evaluation of experimental autoimmune
encephalomyelitis
Mice were 8 to 14 weeks of age at the time of immunization.
Experimental autoimmune encephalomyelitis (EAE) was in-
duced by subcutaneous immunization with 60 to 75 μg re-
combinant human myelin oligodendrocyte glycoprotein
protein (rhMOG, AnaSpec) and 800 μg H37Ra (DIFCO
Laboratories) emulsified in complete Freund’s adjuvant
(DIFCO Laboratories) or 200 μl of recombinant human
MOG1–125 Hooke-Kit (Hooke Laboratories) followed by two
subsequent intraperitoneal injections of 300 ng pertussis
toxin (List Biological Laboratories or Hooke Laboratories) at
the time of immunization and respectively one or two days
later. In some experiments 400 ng pertussis toxin was used,
while taking care that controls and testing cohorts received
the same amount. Boost was performed four to six weeks
after immunization via a second subcutaneous injection with
half the amount of the components from the primary EAE
induction. Some mice were boosted with complete Freund’s
adjuvant andMycobacterium tuberculosis only.
Additionally, some animals received a further intraperito-
neal injection of 100 μg ovalbumin (OVA, Sigma-Aldrich)
in Alum (Thermo Scientific) at the days of immunization
and boost with rhMOG.
Animals were assessed daily for the development of
classical EAE signs, which were translated into clinical scores,
as follows: 0 = no disease; 0,5 = tail weakness, 1 = complete
tail paralysis; 1,5 = tail paralysis plus impaired righting reflex,
2 = partial hind limb paralysis; 3 = complete hind leg paraly-
sis; 4 = complete foreleg paralysis; 5 = moribund.
Immunohistology of human tissue
The tissue samples were fixed in 4% paraformaldehyde and
embedded in paraffin. Antigen retrieval of 3 μm thick
Table 1 Characteristics of the biopsy cases examined
Sample ID Diagnosis Presence CD138+
Ki67− cells
Age Treatment Time from first
symptoms to biopsy
MS 1 Acute multiple sclerosis + 50 none 4 weeks
MS 2 Acute multiple sclerosis + 22 High dose steroids
two weeks prior to biopsy
8 weeks
MS 3 Secondary progressive multiple sclerosis + 66 Mitoxanthrone 14 years
MS 4 Acute multiple sclerosis + 58 unknown 9 years
OND 1 Anti-GABA-B receptor encephalitis + 50 unknown unknown
OND 2 Whipple’s disease + 40 unknown 2 years
OND 3 Tuberculosis + 49 none unknown
OND 4 Progressive multifocal leukoencephalopathy after
immune reconstitution syndrome (PML-IRIS)
+ 54 anti-HIV (HAART) unknown
OND 5 IgG4-related disease + 45 none inknown
MS multiple sclerosis, OND other neurological disease
Table 2 Characteristics of the autopsy cases examined
Sample ID Diagnosis Presence of
CD138+ cells
Age
died
Treatment Disease
duration
Lesion localization Lesion activity
MS 5 Secondary progressive
multiple sclerosis
+ 66 Tamoxifen 21 years juxtacortical chronic active
MS 6 Multiple sclerosis + 44 Morphine and Baclofene 22 years cortex chronic active
MS 7 Multiple sclerosis – 57 Antibiotics, Morphine, Insuline 27 years cortex chronic active
MS 8 Multiple sclerosis – 56 Paracetamol, Cannabis tea, Vitamine D 32 years cortex and white matter chronic active
MS 9 Secondary progressive
multiple sclerosis
+ 58 Morphine and Midazolam 18 years white matter chronic active
MS multiple sclerosis
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deparaffinized sections was performed in 10 mM cit-
rate buffer for 3 min in a pressure cooker. Sections were
blocked with PBS/ 5% FCS for 20 min, afterwards the sec-
tions were stained with antibodies in PBS/ 5% FCS/ 0.1%
Tween20 for minimum 45 min. Following antibodies were
used: 4′,6-diamidino-2-phenylindole (DAPI) (Sigma);
mouse anti-human-Ki67 (clone Mib-1, DAKO), anti-
mouse-Alexa Fluor 546 (polyclonal goat, LifeTechnologies);
anti-CD138-FITC (MI15, Biolegend). Sections were
mounted with Fluoromount™ Aqueous Mounting Medium
(Sigma-Aldrich). Confocal images were generated using a
20×/0.5 numerical aperture (NA) air objective lens on a
Zeiss LSM710, provided with Zen 2010 Version 6.0 soft-
ware. Images were analyzed using Zen 2009 or 2011 Light
Edition software (Carl Zeiss MicroImaging).
In-vivo EdU-pulse chase method
Each mouse received 2,5 mg 5-ethynyl-2′-deoxyuridine
(EdU) per day (Invitrogen) and glucose (Braun) per drinking
water. Freshly prepared EdU-water was exchanged every two
to three days. If rhMOG-immunized mice were unable to
drink anymore from the bottle, the same amount of EdU
was administered as agarose-gel pad. The treatment after the
boost began at day 28 and ended at day 42. Some mice were
analyzed on the day of stopping the EdU-feeding (pulse
group), others after a three- to five-week chase period (chase
group) as indicated in the figure legends.
Enzyme-linked immunosorbent assay
96-well flat bottom plates (Corning) were coated with
50 μl of a 10 μg/ml anti-mouse Ig (anti-mouse IgM, IgG
and IgA, Southern Biotech) or recombinant human
MOG1–125 protein (AnaSpec) solution overnight at 4 °C.
After blocking with PBS/ 3% BSA for 1 h at 37 °C, serum
was added, serial dilutions were prepared and plates
were incubated for 1 h at 37 °C. For detection, 50 ng bi-
otinylated anti-Ig (anti-mouse IgM, IgG, and IgA, South-
ern Biotech) were added for 1 h and 50 ng ExtrAvidin®–
Alkaline Phosphatase (Sigma-Aldrich) for 20 min both
at room temperature. Alkaline Phosphatase Yellow Li-
quid Substrate (Sigma-Aldrich) was used for detection.
As standard, sera from Th mice immunized with recom-
binant murine MOG1–125 (Anaspec) were pooled. There-
fore, mice were subcutaneously immunized with 30 to
100 μg recombinant murine MOG (Anaspec) and
800 μg H37Ra (DIFCO Laboratories) emulsified in
complete Freund’s adjuvant (DIFCO Laboratories)
followed by two subsequent intraperitoneal injections of
200 to 400 ng pertussis toxin (List Biological Laborator-
ies) at the time point of immunization and 2 days later.
The sera of Th mice immunized with recombinant
mouse MOG were pooled and used as standard for
enzyme-linked immunosorbent assay as they have high
MOG-specific antibody titers.
All determined concentrations of antibodies were nor-
malized to this standard. Serum from untreated C57BL/6
mice was used as a negative control.
Preparation of histological sections and microscopy
For tissue fixation, mice were lethally anesthetized and
transcardially perfused with ice cold PBS followed by 4%
paraformaldehyde. Spinal cord and brain were isolated and
further fixed in 4% paraformaldehyde for minimum 4 h up
to overnight at 4 °C. Afterwards, organs were prepared for
freezing in 15% and 30% sucrose PBS solution each over
night at 4 °C. Spinal cord was cut into 8 segments length-
wise, and the spinal cord segments were embedded in
O.C.T. compound (Tissue Tek) for cryo conservation and
quickly frozen in 2-methylbutan placed on 96% ethanol
cooled with dry ice. Samples were stored at −80 °C until
preparation of tissue sections. For histological staining, sec-
tions of 10 μm were rehydrated in PBS for 20 min and
blocked with 10% rat serum (StemCell Technologies) and/
or 10% goat serum (Sigma) in PBS/ 1% BSA/ 0,1% Tween20
for 30 min. Afterwards the sections were stained with
antibodies in PBS/ 1% BSA/ 0,1% Tween20 for minimum
1 h. Following antibodies and reagents were used: 4′,6-
diamidino-2-phenylindole (DAPI) (Sigma); anti-a prolif-
eration inducing ligand (APRIL, clone A3D8, BioLegend),
anti-hamster (Armenian)-IgG-FITC (clone Poly4055,
BioLegend), anti-mouse-B-cell activating factor (BAFF)-
Alexa Fluor 546 (clone 121,808, R&D Systems,DRFZ);
anti-mouse-B220-Alexa Fluor 488, 594 and 647 (clone
RA3.6B2, DRFZ); anti-CXCL12-digoxygenin (DIG) (clone
79,018, R&D systems, DRFZ); anti-DIG-Alexa Fluor 546
and 594 (DRFZ); anti-GFAP-Alexa Fluor 488 (clone GA5,
eBioscience); anit-mouse-Iba1 (polyclonal rabbit, Wako
Pure Chemical Industries); anti-rabbit-IgG-Alexa Fluor
594 and 647 (polyclonal donkey, Invitrogen); anti-mouse-
IgA-Alexa Fluor 594 (clone 11–44-2, Southern Biotch,
DRFZ); anti-mouse-IgG-Alexa Fluor 546 (polyclonal goat,
Life Technologies); anti-mouse-IgM-Alexa Fluor 546 and
Cy5 (clone M41, DRFZ); anti-mouse-kappa light chain-
Alexa Fluor 488, 546, 594 and FITC (clone 187.1, DRFZ);
anti-mouse-lambda1 light chain-Alexa Fluor 488, 594 and
FITC (clone LS136, DRFZ); anti-laminin (polyclonal
rabbit, Sigma); anti-mouse-VCAM-1-Alexa Fluor 488
(clone 6C71, DRFZ). EdU staining was performed using
the Click-iT™ EdU Imaging Kits with Alexa Fluor 555, 594
or 647 (Invitrogen). Sections were mounted with
Fluoromount™ Aqueous Mounting Medium (Sigma-
Aldrich). Confocal images were generated using a 20×/0.5
numerical aperture (NA) air objective lens on a Zeiss
LSM710, provided with Zen 2010 Version 6.0 software.
Images were analyzed using Zen 2009 or 2011 Light
Edition software (Carl Zeiss MicroImaging).
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Histological quantification procedures
The isotype expression of plasma cells as well as the EdU
uptake of plasma cells was determined by manual counting
of recorded histological images. The number of analyzed
plasma cells was indicated in the figure legends.
To quantify the contribution of Iba1- or GFAP-positive
cells to BAFF production, we determined the pixel overlay
of the 2 channels (BAFF and Iba1 or BAFF and GFAP, re-
spectively) using Fiji Image J software [60]. Subsequently,
the ratio of double positive pixels to all BAFF-positive
pixels was calculated. Six images from four mice for each
time point were analyzed.
Immunohistochemistry
Immunohistochemical staining of human tissue sections
was done with the BenchMark XT ICH/ISH staining
module by using the avidin-biotin-complex-method. The
following antibodies were used: CD3 (DAKO), CD4
(Zytomed), CD8 (DAKO), CD20 (DAKO), CD68 (DAKO),
CD138 (DAKO), Ki67 (DAKO) and MBP (myelin basic
protein, A. Menarini Diagnostics). Pictures were taken with
a microscope BX50 (Olympus) using a 40× objective lens.
Inflammation was assessed with H&E (Merck) accord-
ing to standard procedures. Pictures were taken with a
compact microscope BZ-9000 (Keyence) using a 10× ob-
jective lens. Images were analyzed using Keyence Analyzer
software (Keyence).
Cell preparation and flow cytometry
Mice were lethally anesthetized and transcardially perfused
with ice cold PBS. Brain, spinal cord and bone marrow
were isolated and single cell solutions prepared. The re-
moved CNS was triturated through a 70 μmmesh and lym-
phocytes were isolated using 35% Percoll as myelin
remained onto the Percoll and could be separated. Directly
after lymphocyte isolation, cells were incubated with 20 μg/
ml anti-FcgRII/III (clone 2.4G2, DRFZ) in PBS/ 0.2% BSA
solution for 10 min at 4 °C. Surface staining was performed
using following antibodies: anti-mouse-CD3-FITC (clone
145-2c11, DRFZ); anti-mouse-CD19-Pacific Blue (clone
1D3, DRFZ); anti-mouse-CD4-Alexa Fluor 647 (clone
GK1.5, DRFZ); anti-mouse-CD45.2-allophycocyanin (APC)
(clone 104, eBioscience); Fixable Viability Dye eFluor®780
(eBioscience). For intracellular staining cells were fixed and
permeabilized with BD Cytofix/Cytoperm (BD Bioscience)
and stained with anti-mouse-kappa light chain-FITC (clone
187.1, DRFZ) and anti-mouse-lambda1 light chain (clone
LS136, DRFZ). EdU staining was performed using the
Click-iT™ EdU Imaging Kit with Alexa Fluor 594 (Invitro-
gen). Stained samples were inquired with a BD LSRFortessa
cytometer (BD Biosciences) or a MACSQuant (Miltenyi).
Flow cytometric data were analyzed with FlowJo (Tree Star,
Inc.) software.
Statistics
Statistical analysis was performed with GraphPad Prism 6
software, the corresponding tests for significance are spe-
cified in the figure legends. P values <0.05 were considered
significant, no correction for multiple comparisons was
made due to the exploratory nature of the study.
Results
Non-proliferating plasma cells are present in the CNS of
multiple sclerosis patients
When analyzing human central nervous system (CNS) tis-
sue from patients with multiple sclerosis (n = 7) and other
neurological diseases (OND, n = 5) (Tables 1 and 2), plasma
cells (CD138+) were found at various locations, including
parenchymal, perivascular and meningeal areas (Fig. 1a,
Additional file 1 Fig. S1). The majority of plasma cells in
the CNS of multiple sclerosis patients, as well as in other
inflammatory brain conditions were non-proliferating, as
shown by a lack of the proliferation marker Ki67 (Fig. 1a,
Additional file 1 Fig. S1), suggesting that these plasma cells
could be long-lived. Representative serial pictures were re-
corded in order to characterize the immune cell infiltration
and demyeliniation in the same patient (Fig. 1b). As there
are no methods available specifically addressing the lifetime
of plasma cells in the chronically inflamed CNS of humans,
we decided to move to a mouse model, allowing us to
pulse-label proliferating plasma cells by 5-ethynyl-2′-deox-
yuridine (EdU) and thereby tracking their lifetime.
Adaptation of EAE mouse model to generate a memory
response
To address this further, we first analyzed plasma cell
distribution and longevity in a mouse model of chronic
neuroinflammation. Hence, we immunized mice with hu-
man recombinant myelin oligodendrocyte glycoprotein
(rhMOG), which leads to a known B cell- and antibody-
dependent experimental autoimmune encephalomyelitis
(EAE) [40, 42, 49]. To avoid the known limitations of
C57BL/6 EAE models (only one flare of activity), and ac-
count for the fact that long-lived plasma cells are generated
in memory responses [20], we modified the immunization
protocol to generate a model of relapsing disease: at day 28
after the initial induction, we boosted mice with rhMOG as
a secondary immunization in order to induce a memory
immune response and a peak after boost. Analyzing the
clinical data of the mice after boost, 67% of immunized
mice developed a second peak with a mean onset of symp-
toms at day 36 after EAE induction and concordant max-
imum disease severity score of 2.1 compared to the first
peak (2.1) (Fig. 2a, Table 3). The mean day of clinical onset
after boost was four days earlier than during the initial EAE
course (Fig. 2b and c, Table 3). Next, we characterized the
EAE lesions in our boost model by histology. This analysis
revealed massive lymphocyte and macrophage infiltration
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associated with demyelination in the spinal cord, compared
to CNS of control mice immunized with adjuvant only
(Additional file 2 Fig. S2).
To investigate the dependence on antigen for the in-
duction of the second peak, we immunized mice with
rhMOG and boosted them with complete Freund’s adju-
vant and Mycobacterium tuberculosis only. As expected,
EAE symptoms did not increase after boost in these
mice (data not shown). Furthermore, we analyzed the
serum immunoglobulin as a read-out of plasma cell
function. Total and MOG-specific immunoglobulin was
significantly increased in mice that were immunized and
boosted with rhMOG, compared to unimmunized mice
(Fig. 2d). Importantly, a strong increase in MOG-specific
auto-antibodies was also observed when mice after boost
were compared to mice analyzed during the first chronic
phase (Fig. 2d, right). Supporting our findings, we ob-
served only a slight increase of total immunoglobulin of
mice immunized and boosted with MOG peptide (amino
acids 35–55) compared to boosted rhMOG EAE mice,
but without the significant increase of MOG-specific
auto-antibodies compared to unimmunized mice
(Additional file 3 Fig. S3 and Additional file 4 Supple-
mentary Methods), indicating that the rhMOG protein,
but not MOG peptide, are capable of anti-MOG auto-
antibody induction.
Plasma cells persist in the CNS of EAE mice and become
long-lived
To investigate if plasma cells can become long-lived dir-
ectly in the inflamed CNS of EAE mice, dividing cells
were labeled during the first two weeks after boost by
feeding EdU (Fig. 3a), which incorporates into newly syn-
thesized DNA [59]. Mice were analyzed either directly
after stopping EdU-feeding (pulse cohort) or three to five
weeks after stopping the EdU-gavage (chase cohort).
Histological analysis of CNS sections revealed EdU+ as
well as EdU− plasma cells in the meninges of the chase
cohort (Fig. 3b). Directly after the pulse, approximately
one third of total plasma cells were EdU+, and the same
proportion remained positive after the chase period in
the CNS (Fig. 3c), indicating that there were no major
Fig. 1 Non-proliferating plasma cells in the brain of multiple sclerosis patients. a DAPI (blue), CD138 (green) and Ki67 (red) were stained in the
CNS of patient biopsies with multiple sclerosis (n = 4). Representative images are shown. Scale bar represents 50 µm. b HE, MBP, CD3, CD8, CD4,
CD68, CD20 and CD138 staining was performed in the CNS of patients with multiple sclerosis (n = 5) in serial slides. Representative images of
one patient are shown. Scale bars represent 100 μm.
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Fig. 2 Characterization of EAE-boost model. Mice were immunized and boosted (day 28) with rhMOG. a Daily clinical EAE scores are shown.
Graph depicts mean value and standard deviation of 48 animals pooled from ten independent experiments. b The clinical outcome during the
first (control group) and the second (boost group) peak was directly compared. Graph depicts mean value and standard deviation of 48 animals
pooled from ten independent experiments. c The day of onset was compared between the first (control group) and the second (boost group)
peak. The differences between the groups were tested with the Log-Rank (Chi Square) test (***P < 0,001). d Graphs demonstrate relative standard
concentration of total (left) and MOG-specific immunoglobulin (right) in serum of mice untreated, immunized or boosted, analyzed in the chronic
phase. Bars represent mean, each dot represents one mouse pooled from eight (immunized) and five (boost) individual experiments. The
statistical differences were tested with the unpaired Mann-Whitney U test (*P < 0,05, ***P < 0,001)
Table 3 Features of EAE development after disease induction and additional boost
Incidence Day of onset Maximum score Number of animals without
relapse after boost
Number of animals with signs
occuring after boost only
EAE induction 69/88 (78,4%) 12,3 ± 1,8 2,1 ± 1,2 – –
Boost 59/88 (67,1%)a 36,1 ± 1,6b 2,1 ± 1,0c 15/88 (17,1%)d 9/88 (10,2%)
aIncrease of scores of ≥0,5
bAt day 28 boost was performed
cIncludes clinical scores from animals with constant scores after boost
dAnimals developed peak after EAE induction, but scores remained stable after boost
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changes such as proliferation, migration or apoptosis in-
fluencing the CNS-resident plasma cell compartment in
the intervening three to five weeks. Interestingly, half of
the long-lived plasma cells were class-switched (Fig. 3d
and e). These results show for the first time that long-
lived plasma cells can persist in the CNS under
Fig. 3 Long-lived plasma cells persist in the chronically inflamed CNS. Mice were immunized and boosted (day 28) with rhMOG. a The scheme
demonstrates the experimental procedure for the EdU pulse-chase experiment, starting after boost. The mice received EdU for 14 days via
drinking water. Analysis was performed either directly after stopping EdU-feeding or five to seven weeks after boost. b A representative
confocal tile scan of a total spinal cord section from day 77 after boost is shown. Signals after immunofluorescence staining of EdU (red),
antibody-secreting cells (κ/λ, green) and DAPI (blue) are shown. Data are representative of six mice from three independent experiments. Scale bar
of the tile scan represents 200 μm, scale bar of the magnified inset represents 50 μm. c The frequency of EdU+ plasma cells was determined
directly after stopping EdU-feeding (pulse) and after a chase period three to five weeks later. 64 to 362 antibody-secreting cells of each mouse
were counted and analyzed manually, mice are pooled from three independent experiments. Bars indicate mean, each data point indicates an
individual mouse. d Representative confocal microscopy images of inflamed spinal cord of five EAE mice analyzed three to five weeks after
stopping EdU-feeding are shown. Antibody-secreting cells (κ/λ, green), EdU (red), DAPI (upper row, blue), IgG (lower panel, left, blue) or IgA
(lower panel, right, blue) were stained. Five mice from two independent experiments were analyzed. Scale bars represent 20 μm. e The graph
demonstrates the frequency of IgM+ and IgG+/IgA+ EdU+ plasma cells after the chase period. 52 to 70 EdU+ plasma cells of each mouse were
counted manually. Bars indicate mean, each data point indicates one individual mouse pooled from two independent experiments. f Bone
marrow lymphocytes of EAE mice were isolated and analyzed by flow cytometry three to five weeks after stopping EdU-feeding. Viable
(eFluor780−) lymphocytes (CD45.2+) were further analyzed for kappa and afterwards for EdU. Bars indicate mean, each data point indicates
one individual mouse. Data of two independent experiments are shown. The significance between the groups was tested with the unpaired
Mann-Whitney U test (**P < 0.01)
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conditions of chronic inflammation, similar to what has
been shown in other inflamed organs as e.g. in the kidney
[6, 26]. Notably, we also detected other, kappa/lambda
negative, lymphocytes that had taken up EdU in our sec-
tions, some of them were CD4+ or CD19+ as determined
by flow cytometry (data not shown) suggesting that not
only long-lived plasma cells, but also memory B and T
cells, which were generated during the first two weeks
after the boost, were found to persist in chronically in-
flamed CNS. The challenge with rhMOG also resulted in
the accumulation of EdU+ plasma cells in the bone mar-
row (Fig. 3f ). When comparing the frequency of EdU+
plasma cells in both organs, we noticed that the number
of plasma cells drops to a greater extent in the bone mar-
row than in the CNS. Although oligoclonal bands are a
key criterion for the diagnosis of multiple sclerosis, the
specificity of plasma cells in the CNS is largely unknown.
In another neuroinflammatory disorder, anti-N-methyl-
D-aspartate receptor (NMDAR) encephalitis, B cells and
antibody-secreting cells in the CNS were found to have B
cell receptor specificities which recognize CNS struc-
tures, as well as B cells with other specificities [31].
In order to test for the specificity of CNS-resident plasma
cells, we modified our EAE protocol by co-challenging the
mice with an antigen irrelevant for neuroinflammation
(ovalbumin, OVA) at the time of MOG injection (Fig. 4a).
We chose OVA because it allows us to detect plasma cells
specific for this antigen in the tissue by immunofluores-
cence microscopy [35]. Indeed, plasma cells containing
OVA-specific antibodies, identified by staining with fluores-
cently tagged OVA, could be detected in the CNS of EAE-
diseased mice (Fig. 4b). Notably, OVA-specific plasma cells
also had the capability to persist in the chronically inflamed
CNS, as indicated by the presence of EdU+ OVA-specific
plasma cells after the chase period.
Plasma cell survival niches emerge in the chronically
inflamed CNS
Next, we further characterized the localization and
phenotype of antibody-secreting cells in the chronically
inflamed CNS. Plasma cells were found in the meninges
and in the perivascular parenchyma (Fig. 5a) in the prox-
imity of B cells (Fig. 5b), confirming previous reports
[38, 55]. The majority of the plasma cells were class-
switched and only approximately 1/10 (12%) were IgM+
(Fig. 5c and d), characteristic of a memory response.
The survival of long-lived plasma cells has been shown
to depend on extrinsic factors [58]. By histology, we in-
vestigated the presence of these factors in the acute and
chronically inflamed CNS. In line with previous reports
Fig. 4 Long-lived plasma cells with non-neuronal or non-self specificities for neuroinflammation persist in the chronically inflamed CNS only to a
very low extent. a The scheme demonstrates the experimental procedure for EdU pulse-chase experiment starting after boost with additional
application of ovalbumin (OVA). The mice were immunized and boosted with rhMOG and OVA. Afterwards, they received EdU for 14 days via
drinking water. Analysis was performed directly after stopping the EdU-feeding or five weeks after boost. b A representative confocal
image of spinal cord from day 42 after boost is shown. Signals after immunofluorescence staining of antibody-secreting cells (κ, green),
DAPI (left, blue), EdU (red) and OVA (right, blue) are shown. Data of four mice pooled from two independent experiments are shown.
Scale bar scan represents 50 μm
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that showed an increased expression of CXCL12 on
blood vessel walls and parenchyma in multiple sclerosis
patients [33, 44] and in peptide induced EAE mice [45],
we could detect an upregulation of CXCL12 in the lam-
ina glia limitans, the meninges and in the parenchyma at
the peak of the disease (Fig. 6a). In addition, we found a
persistence of elevated CXCL12 compared to healthy
controls in circumscribed tissue regions in the paren-
chyma and the meninges in the chronic phase (Fig. 6a).
The signal partly overlapped with GFAP staining,
indicating astrocytes as producers of CXCL12, in line
with previous reports [4, 33, 44]. Notably, plasma cells
were found to localize in CXCL12+ areas (Fig. 6a, right
lower panel), supporting the idea that CXCL12 plays a
role in attracting plasma cells to inflammatory niches, in
addition to its role in mediating plasma cell migration to
their physiologic survival niches in the bone marrow
[23]. No CXCL12 upregulation was detected when mice
were immunized with complete Freund’s adjuvant and
Mycobacterium tuberculosis (Fig. 6a, left lower panel).
Fig. 5 Antibody-secreting cells reside in a supportive microenvironment inflamed mouse CNS during the second peak of EAE. Mice were
immunized and boosted (day 28) with rhMOG. Analysis of the spinal cords was performed during the peak after boost. a The boundaries of the
meninges and the parenchyma are visualized after staining with anti-GFAP (red) and anti-laminin (right, blue) antibodies to determine the relative
localization of plasma cells (κ, green) in the inflamed CNS of EAE mice. Representative images of three mice of two independent experiments are
shown. Scale bars represent 50 μm. b Representative confocal microscopy image of inflamed spinal cord are shown. Antibody-secreting cells
(κ, green) are located in the subarachnoid space in the meninges in the proximity of B220+ B cells (red). c Representative confocal microscopy
images of inflamed spinal cord of EAE mice are shown after IgA, IgG and IgM (red) isotype staining of antibody-secreting cells (κ/λ, green). Six
mice from three independent experiments were analyzed. Scale bars represent 20 μm. d The graph demonstrates the frequency of IgM+ or class-
switched plasma cells in spinal cord at peak after boost. 51 to 209 antibody-secreting cells each of six mice pooled from three independent
experiments were counted und analyzed manually. Bars indicate mean, each data point represents one individual mouse
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Plasma cell survival niches are characterized by a syn-
ergy of multiple molecules which act together in order to
support the longevity of their inhabitants. In addition to
the chemokine CXCL12, which is involved in attracting
plasmablasts into their niches, the adhesion of plasma
cells in their niches is thought to be mediated at least
partly by VCAM-1, which interacts with the adhesion
molecule VLA-4 on plasma cells [14]. In line with pub-
lished results [17], we could detect an upregulation of
VCAM-1 in the CNS of mice affected by EAE at the peak
of disease (Fig. 6b). In contrast, a signal for VCAM-1 was
restricted to endothelial cells in healthy control mice. In
addition, although VCAM-1 expression was reduced
during the chronic phase compared to peak (Fig. 6b),
we still detected a focal upregulation when compared
to healthy mice, and, importantly, plasma cells colocalized
at areas of increased VCAM-1 expression, supporting the
idea that these areas marked niches in which plasma cells
accumulate.
Next, we investigated the presence of survival factors for
plasma cells at these locations. Plasma cell survival in the
bone marrow has been shown to depend on signaling
transmitted by the receptor B cell maturation antigen
(BCMA) [3, 47]. Indeed, we were able to detect an in-
crease in the signal of BCMA ligand B-cell activating
factor APRIL by immunofluorescence staining of CNS
tissue sections from mice at the peak of EAE compared to
healthy controls (Fig. 7a, left panel). In addition to APRIL-
positive cells morphologically resembling astrocytes, we
also detected ovoid-shaped cells that showed a strong
positivity when stained with an anti-kappa light chain
antibody, indicative of plasma cells. These cells remained
strongly positive for APRIL, also during the chronic phase
(Fig. 7a, right panel). Co-staining for EdU confirmed
that long-lived, kappa+ cells with plasmacytoid morph-
ology were positive for APRIL in chronic EAE (Fig. 7b).
In conclusion, these results show that the plasma cell sur-
vival factor APRIL is produced in the inflamed CNS. In
Fig. 6 Plasma cell niche signals CXCL12 and VCAM-1 persist in chronically inflamed mouse CNS. Mice were immunized and boosted (day 28) with
rhMOG. Analysis of the spinal cords was performed at different time points as indicated. a Histology staining was performed with DAPI (blue),
anti-CXCL12 (red), anti-GFAP (green) and anti-kappa (κ, right lower panel green) antibody. To determine CXCL12 expression in control CNS, the spinal
cord of mice immunized with complete Freund’s adjuvant and Mycobacterium tuberculosis, was stained. Only minimal CXCL12 immunoreactivity was
detected in the parenchyma. Three to five mice from two independent experiments were analyzed. Scale bars represent 100 μm in the upper panel
and 50 μm in the lower panel. b DAPI (blue) and VCAM-1 (green) was stained in spinal cord sections of EAE (upper panel) and control mice (lower
panel). Three mice from two independent experiments were analyzed per disease stage. Scale bars represent 50 μm
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addition to astrocytes, also plasma cells themselves
may be a source of APRIL in the CNS, consistent
with previous findings in other autoimmune models
[9]. We could also find an elevated expression of
another BCMA ligand, BAFF, in histology during the
EAE peak compared to healthy controls (Fig. 8). Iba1
and GFAP staining revealed both microglia and
astrocytes as contributors to BAFF production at the
peak of disease: Within the cells showing BAFF posi-
tivity by histology, microglia and astrocytes contrib-
uted both, as about 30% ± 11% of all BAFF+ cells
were Iba+, and 55% ± 2% co-stained for GFAP. They
were also the main populations producing BAFF
during the chronic phase of EAE (Iba1: 30% ± 12%;
Fig. 7 Expression of APRIL in inflamed mouse CNS. Mice were immunized and boosted (day 28) with rhMOG. Analysis of the spinal cords was
performed at time points as indicated. a The fluorescence signal of DAPI (blue), APRIL (green) and kappa (κ, red) is shown. Magnified insets of the
framed area are shown in the right corner. To determine APRIL expression in control CNS, the spinal cord of mice immunized with complete
Freund’s adjuvant and Mycobacterium tuberculosis was stained (lower panel). Three to four mice from two independent experiments were
analyzed. Scale bars represent 50 μm. b The mice received EdU for 14 days via drinking water after the boost (day 28). DAPI (blue), kappa (κ,
green), EdU and APRIL staining were performed three weeks after stopping the EdU feeding. Four mice from two independent experiments were
analyzed. Scale bar represents 20 μm
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GFAP: 53% ± 3%). In addition to the parenchyma,
BAFF was also present in meningeal areas, and B
cells as well as plasma cells accumulated specifically
in these regions (Additional file 5 Fig. S4). Notably, B
cells and plasma cells were found to stain postitive
for BAFF in these regions.
Taken together, these findings reveal CNS-resident
cells as well as B-lineage cells to stain positive for the
BCMA ligand BAFF. Thus, we suggest that both CNS-
resident and blood-derived cells support the survival of
plasma cells in inflammatory niches.
Discussion and conclusions
Although B cells became a focus of multiple sclerosis re-
search in the last decade and cerebrospinal fluid (CSF)
oligoclonal bands are a hallmark in the diagnosis of the
disease, little is known about the role of plasma cells in
its pathogenesis.
During immune responses, B cells in secondary lymphoid
organs differentiate into antibody-secreting plasmablasts.
Most of these plasmablasts are short-lived and die within a
few days [63], however, a fraction of them migrates in a
CXCL12-dependent fashion to the bone marrow, where
they persist as resident plasma cells, given that they reach
their physiologic survival niches in the bone marrow [18,
20, 75]. While the number of plasma cells reaching the
bone marrow is rather small in primary responses, memory
immune responses boost the number of long-lived plasma
cells persisting in this organ [20, 41]. The relapsing charac-
ter of multiple sclerosis also has traits of a memory im-
mune response as the relapses lead to repetitive exposure
of the immune system to (auto)antigens [51].
In autoimmune models, antibody-producing cells ac-
cumulate and can become long-lived in inflamed tissue
[6, 65], where they may produce protective or patho-
genic auto-antibodies [27, 73]. Here, we detected long-
Fig. 8 Expression of BAFF in inflamed mouse CNS. Mice were immunized and boosted (day 28) with rhMOG. Analysis of the spinal cords was
performed at indicated time points. The fluorescence signal of DAPI, BAFF, GFAP and Iba1 is shown. To determine BAFF expression in control
CNS, the spinal cord of mice immunized with complete Freund’s adjuvant and Mycobacterium tuberculosis was stained. Scale bars represent
100 μm (peak after boost) and 50 μm (chronic phase after boost and control). Four mice from two to three independent experiments were
analyzed for each disease stage
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lived 5-ethynyl-2′-deoxyuridine (EdU)-positive plasma
cells generated in a memory response against MOG in
the CNS of mice (Fig. 3). Interestingly, the ability of
plasma cells to persist in the CNS was somewhat greater
than in the bone marrow, as indicated by the greater loss
of EdU+ bone marrow plasma cells between the pulse
and the chase period (Fig. 3f ).
Our finding that ovalbumin (OVA)-specific plasma cells
can also persist in the CNS suggests that this persistence is
independent of antigen-specificity, similar to what has been
demonstrated for plasma cells in the inflamed kidneys of
lupus mice [6], and consistent with the finding that plasma
cell survival is independent of the presence of their specific
antigen [41]. In line with our results, an increase of anti-
body indices against non-CNS antigens can be found in
multiple sclerosis patients, the most prominent is the MRZ
reaction, composed of three antibody indices against mea-
sles, rubella and varicella zoster virus. Notably, it is used as
a diagnostic marker for multiple sclerosis patients as it is
absent in other inflammatory neurological diseases [28].
Plasma cell survival has been shown to be independent
of antigenic stimuli [41], but rather depends on cyto-
kines such as the BCMA-ligand A proliferation inducing
ligand (APRIL) [47, 52], in combination with adhesion-
dependent signals [14]. The tumor necrosis factor ligand
superfamily receptor B cell maturation antigen (BCMA)
on plasma cells is known to induce Mcl-1 as a crucial pro-
survival pathway in long-lived plasma cells [52]. In the
bone marrow, the main ligand for BCMA on long-lived
plasma cells is APRIL, produced by eosinophils [10],
which constitute transient inhabitants of the plasma cell
survival niches [75]. In addition to APRIL, BCMA also
binds B-cell activating factor (BAFF), and redundant roles
for BAFF and APRIL in supporting plasma cell survival
have been demonstrated [3]. These factors have been
shown to be present at elevated levels in the cerebrospinal
fluid of multiple sclerosis patients [34, 70]. In line with
this, we could detect elevated levels of these factors at the
peak, and also during the chronic phase in the CNS of
EAE mice, compared to healthy controls (Figs. 7 and 8).
In addition to BCMA ligands, other factors such present
in bone marrow niches, the physiologic site for the main-
tenance of long-lived plasma cells, contribute to plasma
cell survival, among them the chemokine CXCL12 and
the adhesion molecule VCAM-1 [5, 58, 67].
It is known that CXCL12 is expressed in inflamed tissue
[57]. Moreover, CXCL12 has been previously shown to be
expressed in the CNS during both multiple sclerosis and
EAE, leading to compartmentalization of immune cell sub-
types [62]. Here, we detected antibody-secreting cells in
proximity to CXCL12+ cells, presumably astrocytes as
shown by GFAP staining, during the peak of EAE. The ob-
served production of CXCL12 by astrocytes under inflam-
matory conditions is consistent with published data [1, 11,
33]. With regard to plasma cells, CXCL12 serves as the
main factor which attracts those cells to the bone marrow
[18, 20]. CXCL12 is expressed constitutively in high
amounts by reticular stromal cells of the bone marrow [66],
which are a crucial stable component of plasma cell sur-
vival niches [75]. Our finding that CXCL12 production by
astrocytes continues in the chronic EAE phase suggests that
it is involved in creating a microenvironment supportive of
plasma cell persistence in the chronically inflamed CNS.
CXCL12 mediates plasmablast chemotaxis to the survival
niches, however, to what extent it retains plasma cells within
the niches is unclear. VCAM-1 has previously been shown to
support plasma cell survival [5]. In addition, VCAM-1 is
present in plasma cell niches in the bone marrow [68] and
contributes to plasma cell retention at this site, as antibody-
mediated blockade of VLA-4, the receptor for VCAM-1, sig-
nificantly reduces plasma cell numbers in the bone marrow
[14]. In the context of neuroinflammation, VCAM-1 produc-
tion by astrocytes has been previously associated with the
manifestation of neurological disease [17]. The selective accu-
mulation of plasma cells in areas with elevated VCAM-1 ex-
pression during chronic EAE (Fig. 6b) supports the
hypothesis that plasma cells can be retained in CNS survival
niches by the VCAM-1/VLA-4 axis.
In addition to CNS-resident cells such as microglia and
astrocytes, we found B cells and plasma cells staining
strongly positive for both APRIL and BAFF. Our finding is
in line with published results [9], suggesting that B-lineage
cells can promote their survival, proliferation and differenti-
ation in an autocrine pathway. Notably, Chu et al. found
splenic B cells and plasma cells in a mouse model of sys-
temic lupus erythematosus (SLE) express high levels of
BAFF [9], and suggested this as a mechanism for the devel-
opment of this autoimmune disease. Our findings demon-
strate that this mechanism of perpetuation also applies
directly in the target organ of inflammation, and suggest
that this may be a more general mechanism during B cell-
mediated autoimmunity.
Taken together, we identified tissue-resident cells specific-
ally and exclusively present in the CNS, which produce sur-
vival niche signals for long-lived plasma cells during chronic
neuroinflammation. This is in line with our previous findings
that sources of plasma cell survival factors have been shown
to differ between tissues, and various tissue-resident cell
types contribute to the formation of the niches [35]. Add-
itionally, they support the hypothesis that these niches can
be generated de novo in chronic inflammation. Thus, we
demonstrate that at least three main factors characteristic for
plasma cell survival niches, which have previously been
shown to support plasma cell longevity in physiologic sites
such as the bone marrow, are induced under inflammatory
conditions in the CNS. These factors affect various, crucial
functions attributed to these niches, namely the regulation of
chemotaxis (CXCL12), adhesion (VCAM-1) and survival
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(APRIL/ BAFF) of plasma cells, and all three functions are
required for the survival of these cells.
Our finding of Ki67−CD138+ cells in the brain of patients
diagnosed with multiple sclerosis, indicates that non-
proliferative [46] antibody-secreting cells are also present in
the human CNS. In contrast to samples from acute inflam-
matory responses in the CNS, such as progressive multifocal
leukoencephalopathy-immune reconstitution inflammatory
syndrome (PML-IRIS) showing at least a subset of
proliferating CD138+ cells (Additional file 1 Fig. S1),
we could not detect plasma cells in all multiple scler-
osis tissue samples, most probably due to the fact
that the distribution of these cells in the CNS is not
homogeneous and the autopsy/biopsy specimens only
represent small pieces of the CNS. We do not think
that the survival of plasma cells in the CNS is spe-
cific for multiple sclerosis, but rather consider it a
general mechanism of an adaptive immune response
during chronic inflammation, as we could also detect
them in other neuroinflammatory conditions as e.g. in
anti-GABA-B receptor encephalitis (see Additional file 1
Fig. S1) and they are present in other organs as e.g.
in kidneys during lupus nephritis or joints of arthritis
patients [23]. Long-lived plasma cells are sessile in
the tissue [75], and the presence of a CNS-resident
autoantibody-producing plasma cell subset may ex-
plain the effect of anti-VLA4 antibody (natalizumab)
treatment, which hinders lymphocytes from entering
the CNS by blocking the function of α4 integrin on
the surface of immune cells [61], but may also disrupt
plasma cell niches.
Taken together, our findings for the first time demon-
strate the persistence of immune cells in the chronically
inflamed CNS, within inflammatory niches induced de
novo by an immune response. Recently, a crucial role for
CNS stromal cells in the recruitment of antiviral CD8+ T
cells was demonstrated in a mouse model of neurotropic
virus infection [13]. These findings led to the concept of
fibroblastic stromal niches in the CNS, which are capable
of sustaining protective immune cells [53]. Our findings
add another facet to the role of the CNS stroma in sup-
porting immune cell accumulation, as we also find that
stromal cells are able to produce critical factors for the
longevity and persistence of immune cells in a chronic
autoimmune setting. These inflammatory niches share
crucial characteristics with physiologic survival niches for
immune cells, in this case plasma cells, and thereby
support the persistence of these cells, irrespective of their
specificity, even in tissues which are considered virtually
void of peripheral immune cells under healthy conditions.
The selective disruption of such survival niches for long-
lived plasma cells which continually produce autoreactive
antibodies could offer new therapeutic approaches for
chronic neuroinflammatory diseases.
Additional files
Additional file 1: Figure S1. Non-proliferating CD138+ cells in the brain
of patients with other inflammatory neurological diseases (OND). DAPI
(blue), CD138 (green) and Ki67 (red) were stained in the CNS of patient
biopsies with other neurological diseases (OND, n = 4) as indicated on
the left. Representative images are shown. White arrows indicate Ki67+
CD138+ cells. Scale bars represent 50 μm. (TIFF 14779 kb)
Additional file 2: Figure S2. Extensive lymphocyte infiltration during
the peak after boost with rhMOG. To analyze the occurrence of infiltrated
lymphocytes in the inflamed CNS, HE staining was performed. Mice
immunized and boosted with rhMOG (a) were compared to mice
immunized only with complete Freund's adjuvant and Mycobacterium
tuberculosis (b). Six mice of three independent experiments were
analyzed at peak after boost. Scale bar represent 300 μm. (TIFF 13061 kb)
Additional file 3: Figure S3. Comparison of serological antibody titer
after immunization and boost with protein or peptide during chronic
phase. Graphs demonstrate relative standard concentration of total (left)
and MOG-specific immunoglobulin (right) in serum of mice, untreated,
immunized and boosted with rhMOG or immunized and boosted with
MOG35–55, respectively. Bars represent mean, each dot represents one
mouse pooled from five (rhMOG) and two (MOG35–55) individual
experiments. The differences between the groups were tested with the
unpaired Mann-Whitney U test (**P < 0,01 ***P < 0,001). (TIFF 8783 kb)
Additional file 4: Supplementary methods. (PDF 133 kb)
Additional file 5: Figure S4. BAFF-positive B cells and plasma cells in
the inflamed CNS. Mice were immunized and boosted (day 28) with
rhMOG. Analysis of spinal cord was performed during peak after boost.
The fluorescence signal of DAPI (blue), BAFF (red), kappa/lambda (κ/λ,
upper panel green) and B220 (lower panel green) is shown. A plasma cell
is indicated with an arrow. Three mice of two independent experiments
were analyzed. Scale bars represent 50 μm. (TIFF 20356 kb)
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